Open Orphan Share Discussion Threads

[john henry] 03/2/2021 09:04

Market has sold down due to the Finncap note.

[talkman2] 03/2/2021 09:03

Once again fantastic operational news and virtually zero share price response. This is disconcerting.

[mark10101] 03/2/2021 09:02

M5, look at it another way, the brokers notes have been poor the whole coverage of ORPH for the last year, yet ORPH continues to add huge value and grow the share price. A good company to hold as a share holder, do we really want the kiss of death of a some random target.....

Compare to another company I was in prior to moving funds to ORPH Jan last year and they currently sit at 10p having had brokers note for the last 3 years predicting 34p. I am much preferring to be in ORPH and given my experience of brokers notes, I put them in the pile of near useless.

When I was in AVCT last year I got carried away with the brokers notes predicting $b’s of revenues from testing in 2020, I soon woke up and got out at a reasonable price but I just don’t read brokers notes now.

[bobsworth] 03/2/2021 09:02

Typical! Traders now selling on news for a few bob!

finnCap need to go to Specsavers!

No wonder wider market are still unaware of ORPH!

Only thing that will sort this is the publication of results & a forward trading statement.

[talkman2] 03/2/2021 09:01

CF needs to kick Finncap into touch . T

[john henry] 03/2/2021 08:57

Ulterior motive from Finncap bottom draw broker

[lfdkmp] 03/2/2021 08:56

PO'R
£1bn mcap more like £1.50 per share.

[pierre oreilly] 03/2/2021 08:50

Here was me thinking that's 15m of the cash pile gone in the conversion and it turns out it cost orph nowt. FFS c is pretty good. Probably added 10m to the cash pile with pre payments for Ch studies to be done there. So, where's the divi?Shows the value of orphs expertise. If a Ch study can get a drug to market a couple of years earlier than normal, that's worth mega millions to big pharma.I think it must be in the minds of all big pharma to get control of the only company who can do them en mass, so they get their own candidates to market quicker while ensuring other competing drugs get to market much slower. They must be seeing what they'd have to pay for an agreed takeover. C wouldnt let it go now for less than a billion imv, about 70/80p/share

[1gw] 03/2/2021 08:48

Disappointing finnCap note in terms of shareprice target and the revenue that it is based on...

Don't know how they get away with that given CF has said the QM maxes out at about £45m/year and they now have this new facility all but fully-booked for 1H. And then of course there's the Covid challenge studies in the RF once they get the go-ahead.

I would hope CF will remind us (and finnCap) of the main 2021 revenue building blocks this evening.

[lako42] 03/2/2021 08:47

Fantastic work from CF. What a man to have at the helm. I just wish the share price would react in a way that is befitting of his efforts and actual results.

Surely trading this is becoming almost pointless?

[owenski] 03/2/2021 08:43

I would suggest that this spotlights the kind of expertise that OO has, very unusual deal for costs to be funded in this manner, also demonstrates the pent up demand for these kind of studies. Excellent deal. Read below quote -

“This RNS is fantastic news for Open Orphan because we have now, in a very low-cost manner, almost doubled our quarantine bedroom capacity that we hold in our QMB East London facility. We have taken a short-term lease on the former boutique Whitechapel Hotel, the cost of conversion for this new clinic was paid by an existing Open Orphan challenge study client. This client wanted to start their study earlier than the current backlog would have allowed, given that the QMB facility is booked out until the end of 2021. Thus, the cost of converting the hotel into a quarantine unit and also the first year’s lease costs have been funded by this client, therefore there was no net cost to Open Orphan regarding same."

[lako42] 03/2/2021 08:43

Yep, it's becoming our M.O.

[m5] 03/2/2021 08:41

If people want to sell on that news, then crack on.

troutisout3 Feb '21 - 08:35 - 11310 of 11312

Ticks all the boxes, it really does. Well done CF.

[talkman2] 03/2/2021 08:36

Disappointing share price reaction and volume

[troutisout] 03/2/2021 08:35

Yes massive deal, but more importantly it is next to QMB, meaning the staff can all remain where they are and deal with the extra workload from existing lab and offices.

[m5] 03/2/2021 08:34

Yep, I love that. Typical CF doing a deal. Increasing revenue and the cost to that in terms of the lease and fitting it all out costs us nothing. I am impressed with that, that does tickle my fancy!!

[pogue] 03/2/2021 08:32

cheers m5, dam that man is good at getting a deal!!

Link to article


....'We have taken a short-term lease on the former boutique Whitechapel Hotel, the cost of conversion for this new clinic was paid by an existing Open Orphan challenge study client. This client wanted to start their study earlier than the current backlog would have allowed, given that the QMB facility is booked out until the end of 2021. Thus, the cost of converting the hotel into a quarantine unit and also the first year’s lease costs have been funded by this client, therefore there was no net cost to Open Orphan regarding same. '....

Edit
Twice I have been beaten the draw this morning posting a link lol

[m5] 03/2/2021 08:28

Pierre Oreilly3 Feb '21 - 08:21 - 11304 of 11306

Chill out Pierre, I am pulling your chain.

Pogue, CF, on Directors talk.

[lako42] 03/2/2021 08:25

CF will 100% deliver. When that actually reflects in the share price is anyone's guess.

[pogue] 03/2/2021 08:25

m5
where did you read the bit about a client paying for the refurb?

[pierre oreilly] 03/2/2021 08:21

M, I think the evidence is your obsession constantly saying I have an obsession is far worse than anything I could have Anyhows, don't let me keep you from the screen.I think this rns is one of the substantial ones we've been expecting. The one which could start the institutional buying ball rolling and those multi year price rises. Just like Ceres for example.Pretty sure c is now going for the billion quid cap option for orph, and, as usual, he'll deliver.

[m5] 03/2/2021 08:18

Did not cost ORPH a bean for the conversion. How good is that!!!

Paid for by a client. What about that for demand.

[pogue] 03/2/2021 08:09

Lukehold
try this
hTTtps://www.sharesmagazine.co.uk/events/event/shares-investor-evening--webinar-030221